Carl Hart
Mamie Phipps Clark Professor of Psychology (in Psychiatry) at Columbia University
Data updated
Research Footprint
Carl Hart appears in 5 tracked papers (2014–2020), most studied alongside Ketamine and Placebo, across Substance Use Disorders (SUD), Depressive Disorders and Safety & Risk Management.
Most-cited paper: A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial (176 citations).
Frequent co-authors: Elias Dakwar, Edward Nunes and Frances Levin.
Background & Research
Carl L. Hart is a psychologist and neuropsychopharmacologist at Columbia University. His research focuses on the behavioral and neuropharmacological effects of psychoactive drugs in humans, especially factors that influence drug self-administration and potential treatments for substance use disorders. He is also known for public scholarship on drug policy and the harms of criminalization.
Key Impact
He is a leading researcher on human psychopharmacology and substance use disorders, including ketamine and other psychoactive drugs, with influential work on drug self-administration and treatment models.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Carl Hart is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →New York State Psychiatric Institute
State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.
View stakeholder →